Larry L. Wood Sells 18,960 Shares of Edwards Lifesciences Corporation (EW) Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Larry L. Wood sold 18,960 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $114.58, for a total transaction of $2,172,436.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Larry L. Wood also recently made the following trade(s):

  • On Wednesday, November 15th, Larry L. Wood sold 18,960 shares of Edwards Lifesciences stock. The stock was sold at an average price of $104.76, for a total transaction of $1,986,249.60.

Edwards Lifesciences Corporation (NYSE:EW) opened at $114.22 on Friday. Edwards Lifesciences Corporation has a 1-year low of $86.55 and a 1-year high of $121.45. The company has a debt-to-equity ratio of 0.33, a current ratio of 3.49 and a quick ratio of 2.76. The company has a market cap of $24,170.00, a price-to-earnings ratio of 31.67, a PEG ratio of 2.04 and a beta of 0.51.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, October 24th. The medical research company reported $0.84 EPS for the quarter, missing the consensus estimate of $0.86 by ($0.02). The company had revenue of $821.50 million during the quarter, compared to analysts’ expectations of $833.85 million. Edwards Lifesciences had a return on equity of 27.22% and a net margin of 22.47%. Edwards Lifesciences’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same period last year, the firm posted $0.68 EPS. research analysts expect that Edwards Lifesciences Corporation will post 3.76 EPS for the current fiscal year.

Edwards Lifesciences announced that its board has initiated a share buyback plan on Thursday, December 7th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the medical research company to reacquire shares of its stock through open market purchases. Shares buyback plans are typically an indication that the company’s leadership believes its shares are undervalued.

EW has been the subject of a number of recent analyst reports. Canaccord Genuity reiterated a “buy” rating and issued a $135.00 price target (down from $155.00) on shares of Edwards Lifesciences in a research report on Wednesday, October 25th. BMO Capital Markets reiterated a “buy” rating and issued a $132.00 price target on shares of Edwards Lifesciences in a research report on Friday, September 1st. William Blair reiterated an “outperform” rating on shares of Edwards Lifesciences in a research report on Monday, August 28th. SunTrust Banks set a $124.00 price target on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research report on Wednesday, October 25th. Finally, Morgan Stanley dropped their price target on shares of Edwards Lifesciences from $133.00 to $120.00 and set an “overweight” rating for the company in a research report on Thursday, October 26th. Six research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $126.43.

A number of institutional investors have recently added to or reduced their stakes in the stock. Alps Advisors Inc. raised its stake in Edwards Lifesciences by 0.3% during the second quarter. Alps Advisors Inc. now owns 5,102 shares of the medical research company’s stock valued at $603,000 after purchasing an additional 14 shares in the last quarter. Veritable L.P. raised its stake in Edwards Lifesciences by 1.2% during the second quarter. Veritable L.P. now owns 6,244 shares of the medical research company’s stock valued at $738,000 after purchasing an additional 71 shares in the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA raised its stake in Edwards Lifesciences by 2.8% during the second quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 2,776 shares of the medical research company’s stock valued at $320,000 after purchasing an additional 76 shares in the last quarter. Stephens Inc. AR raised its stake in Edwards Lifesciences by 1.2% during the second quarter. Stephens Inc. AR now owns 7,831 shares of the medical research company’s stock valued at $926,000 after purchasing an additional 91 shares in the last quarter. Finally, Johnson Financial Group Inc. raised its stake in Edwards Lifesciences by 7.1% during the second quarter. Johnson Financial Group Inc. now owns 1,639 shares of the medical research company’s stock valued at $194,000 after purchasing an additional 109 shares in the last quarter. 81.82% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Larry L. Wood Sells 18,960 Shares of Edwards Lifesciences Corporation (EW) Stock” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.com-unik.info/2017/12/17/larry-l-wood-sells-18960-shares-of-edwards-lifesciences-corporation-ew-stock-2.html.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit